Pédiatrie [Pediatrics].
Détails
Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Non spécifiée
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_09C64A04EE59
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Pédiatrie [Pediatrics].
Périodique
Revue Médicale Suisse
ISSN
1660-9379
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
8
Numéro
323
Pages
51-56
Langue
français
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Résumé
Several preliminary studies suggest that prophylactic administration of probiotics reduces the incidence of necrotizing enterocolitis (NEC) in preterm infants, and several neonatology units have introduced this treatment under strict surveillance. Nonetheless, breast milk feeding remains the mainstay of NEC prevention. The beta-blocker propranolol, known for its effectiveness on cutaneous hemangiomas, is also proving useful for the treatment of subglottic or visceral hemangiomas. Following the decrease in severe bacterial infections thanks to widespread vaccinations, the McCarthy clinical score has regained importance in the prediction of the risk of bacterial infection in febrile infants. It is easy to use, economical, and has a diagnostic value comparable to laboratory tests. The new WHO growth charts have been introduced in Switzerland in 2011 to take into account the increasing regional and ethnic variations in our country. Any significant change in growth velocity should prompt an evaluation of the need of further investigations.
Mots-clé
Adrenergic beta-Agonists/therapeutic use, Bacterial Infections/complications, Bacterial Infections/diagnosis, Breast Feeding, Enterocolitis, Necrotizing/prevention & control, Fever/microbiology, Growth Charts, Hemangioma/drug therapy, Humans, Infant, Infant, Newborn, Infant, Premature, Diseases/prevention & control, Laryngeal Neoplasms/drug therapy, Mediastinal Neoplasms/drug therapy, Neoplasms/drug therapy, Pediatrics/trends, Probiotics/therapeutic use, Propranolol/therapeutic use, Risk Factors, Skin Neoplasms/drug therapy, Switzerland, Treatment Outcome, World Health Organization
Pubmed
Création de la notice
06/06/2012 18:19
Dernière modification de la notice
02/02/2024 7:31